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Summary
Autoimmunity may contribute to the pathogenesis of chronic obstructive
pulmonary disease (COPD). Studies have identified disease-specific
autoantibodies (DSAAbs) in COPD patients, but natural autoantibodies
(NAAbs) may also play a role. Previous studies have concentrated on circu-
lating autoantibodies, but lung-associated autoantibodies may be most
important. Our aim was to investigate NAAbs and DSAAbs in the circulation
and lungs of COPD smoking (CS) patients compared to smokers (S) without
airway obstruction and subjects who have never smoked (NS). Immuno-
globulin (Ig)G antibodies that bind to lung tissue components were signifi-
cantly lower in the circulation of CS patients than NS (with intermediate
levels in S), as detected by enzyme-linked immunosorbent assay (ELISA).
The levels of antibodies to collagen-1 (the major lung collagen) detected by
ELISA were also reduced significantly in CS patients’ sera compared to NS.
The detection of these antibodies in NS subjects indicates that they are
NAAbs. The occurrence of DSAAbs in some CS patients and S subjects was
indicated by high levels of serum IgG antibodies to cytokeratin-18 and
collagen-5; furthermore, antibodies to collagen-5 eluted from homogenized
lung tissue exposed to low pH (0·1 M glycine, pH 2·8) were raised signifi-
cantly in CS compared to S and NS. Thus, this study supports a role in
COPD for both NAAbs and DSAAbs.
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Introduction
Chronic obstructive pulmonary disease (COPD), involving
chronic bronchitis and emphysema, is characterized by pro-
gressive airflow limitation that is not fully reversible; it is a
major and increasing cause of morbidity and mortality
worldwide [1,2]. Although tobacco smoke is the major
aetiological factor, only 15–20% of smokers develop clini-
cally significant COPD but, once disease is established, it is
progressive, regardless of smoking cessation.
Immune mechanisms are central to the pathogenesis of
COPD, with contributions of both innate and adaptive
immunity [3–14], and the possible involvement of autoim-
munity in COPD has been increasingly recognized [15]. An
association of lung pathology with a variety of well-
characterized autoimmune diseases is evident [16,17], and
cigarette smoking is a risk factor for several recognized
autoimmune diseases [18]. Antibodies specific to a variety
of autoantigens have been described in pulmonary fibrosis
[19–21]. Animal experiments demonstrate that COPD-like
pathology can be generated by autoimmune mechanisms
[22].
More direct evidence for autoimmunity in COPD
patients is provided by reports of autoantibodies (AAb) and
T cells specific for elastin [23,24], although other studies
were unable to confirm this [25–28]. Antibodies to
cytokeratin-18 have also been reported in COPD [29] and
in non-allergic asthma [30]. It has also been proposed that a
broad range of tissue components may serve as
autoantigens in COPD, thereby giving rise to a variety of
AAb whose production differs between patients [25]. This
concept is supported by the demonstration, in differing
proportions of COPD patients, of AAb to pulmonary and
other tissues [31,32] including endothelium [33], carbonyl-
modified proteins [34] and a broad range of tissue-specific
and systemic autoantigens [35,36].
The studies cited above focus on the occurrence of
disease-specific autoantibodies (DSAAb) in COPD, i.e. AAb
Clinical and Experimental Immunology ORIGINAL ARTICLE doi:10.1111/cei.12565
1© 2014 The Authors. Clinical and Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society
for Immunology, Clinical and Experimental Immunology
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use
and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations
are made.
VC r . li i l i t l I l lis J il t l i i i 155
, 180: 155–163
en acces article under the terms of the Creative Com ons Attribution-NonCommercial-NoDerivs Licens , which permits use and
distribu ion in anymediu , provided the original work is pr perly cited, the use is non-commercial and nomodifications or ad ptations rem de.
li ic l I I L I i . / i.
that are detectable in patients but rarely, if at all, in healthy
individuals. A further consideration is the potential involve-
ment of natural autoantibodies (NAAb) that are present in
everyone, but which may take on particular relevance in
disease situations. NAAb are thought to have a variety of
physiological roles, including first line of defence against
infection, clearance of ageing cells and their constituents,
antigen presentation, anti-tumour and anti-inflammatory
activities and immune homeostasis [37]. They show high
‘connectivity’ through idiotype/anti-idiotype interactions
that may account for the fact that, unlike DSAAb, the levels
of detectable NAAb are significantly higher in IgG purified
from serum than they are in whole serum [38,39].
Previous studies have also concentrated on the detection
of circulating AAb in COPD patients, but it could be argued
that AAb sequestered to the lung are most relevant to the
disease process. Thus, the aim of the present study was to
investigate the occurrence of both NAAb and DSAAb in the
circulation and in lung tissue of COPD patients compared
to smokers and non-smokers without COPD.
Materials and methods
Study population
The Nottingham Local Research Ethics Committee (REC)
as well as Nottingham University Hospitals Research and
Development (R&D) approved the study protocol. Written
informed consent was obtained from the participants.
Serum samples were obtained from smokers with
moderate-to-severe COPD (CS) (GOLD stages II–III,
BODE index 2–9), smokers without airway obstruction (S)
and never smokers (NS). COPD diagnosis was defined
according to the American Thoracic Society guidelines,
including spirometry criteria of a forced expiratory volume
in 1 s (FEV1) below 80% of predicted with a FEV1/FVC
(forced vital capacity) ratio of <70% and reversibility of
inhaled beta-2-agonist of <10% or <200 ml absolute
improvement; all were current smokers (Table 1). S and NS
participants underwent pulmonary function tests, which
revealed normal spirometry results (Table 1). Individuals
who had α1-anti-trypsin deficiency, a history of physician-
diagnosed asthma or had a positive skin prick test in
response to the allergens grass pollen, house dust mite, cat
dander or dog hair (ALK-Abello’, Reading, UK) were
excluded from the study. CS patients were also excluded if
they had experienced an exacerbation of disease within the
previous 6 weeks.
Lung samples
Lung samples were obtained from CS patients, S and NS
subjects (five of each). Samples were either donated gener-
ously by GlaxoSmithKline (GSK, Stevenage, UK) or
obtained from Nottingham University Hospitals NHS Trust.
Ethical approval was obtained through GSK and Notting-
ham University Hospitals R&D. Patients in Nottingham
were informed and consented before entering the study.
Lung samples were obtained from Nottingham patients
with COPD who had undergone bullectomy or lung
volume reduction surgery as a part of the management of
severe emphysema. S and NS Nottingham participants were
lung cancer patients who underwent lung biopsy or surgery
in the course of the case management. Normal lung tissue
distal to the tumour, as judged by the pathologist, was used
from these patients’ samples. Lung samples were snap-
frozen in liquid nitrogen and stored at −80°C. The lung
samples provided by GSK were autopsy specimens from CS,
S and NS individuals and were obtained within the normal
framework of autopsy procedures.
Table 1. Demographic characteristic of the study participants who provided serum samples.
CS S NS
Number of patients 6 6 6
Gender Male/female 3/3 1/5 1/5
Age (years) Mean 63·67† 51·83 50·83
Median 65 (54–72) 49·5 (43–63) 51·5 (45–57)
FEV1
(% pred)
Mean 51·50*† 98·50 115·2
Median 53 (17–71) 100·5 (81–119) 110 (103–140)
FVC
(%)
Mean 83·50 106·8 122·2
Median 80 (44–135) 108 (81–128) 115·5 (112–144)
FEV1/
FVC (%)
Mean 61·54*† 92·61 94·60
Median 65·46 (39·4–72·9) 91 (84–101·7) 5·73 (79·1–107·2)
Smoking
(pack/year)
Mean 47·86 29·52 0
Median 57·50 (23·8–62·2) 29·38 (15–42) 0
CS = smokers with chronic obstructive pulmonary disease; S = smokers without airway obstruction; NS = never smokers; FEV1 = forced expiratory
volume in 1 s; FVC = forced vital capacity; Pred = predicted value. *Indicates significant difference between CS and S (P < 0·001). †Indicates significant
difference between CS and NS (P < 0·001).
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Homogenization of human lung tissue samples and
elution of lung-bound antibodies
Lung tissue samples – previously snap-frozen in liquid
nitrogen from CS, S and NS subjects – were defrosted,
adjusted to approximately 0·52 g of tissue and placed on ice.
Samples were cut into small pieces (about 3–4 mm in diam-
eter) and added to 10 ml of ice-cold 10 mM Tris-HCl buffer
pH 7·5 (Sigma Aldrich, Poole, UK) containing one tablet of
complete protease inhibitor cocktail (Roche Diagnostics,
Lewes, UK). Cell disruption was performed using a 2-ml
screw-cap vial filled to three-quarters with 1·0-mm-
diameter glass beads. The remaining vial volume was filled
with preprepared lung tissue pieces and the cap was
secured. Three cycles of tissue disruption were performed
using the Mini-Bead Beater Type BX-4 Cell Disrupter (Glen
Mills Inc., Clifton, NJ, USA), for 30 s each, at 5000 rpm.
Samples were cooled on ice between runs to avoid warming.
Disrupted lung samples were microcentrifuged for 2–4 h, at
17 968 g at 4°C to separate soluble material of the lung
homogenates from the insoluble pellets. Homogenates and
pellets were stored at −20°C to be used in enzyme-linked
immunosorbent assay (ELISA).
For each lung sample fraction, the protein concentra-
tion was determined using a NanoDrop® ND-1000
Spectrophotometer (NanoDrop Technologies, Wilmington,
DE, USA). Antibodies were eluted from the pellets using
elution buffer consisting of cold 0·1 M glycine, pH 2·8
(Sigma Aldrich) and 0·5 M NaCl. Pellet-supernatants were
pipetted several times to mix well and incubated on ice for
1 h with intermittent mixing every 10 min. The pH of the
supernatants was neutralized by the addition of 1 M Tris
pH 8 (Sigma Aldrich) and centrifuged. The protein con-
centration was measured by Nanodrop and the protein
concentrations were standardized to 1 mg/ml. Samples
were diluted 1 : 4 and tested by ELISA for quantitative
measurement of eluted antibodies.
ELISA
ELISA was used for the detection of serum antibodies to
lung tissue or specific candidate antigens. Duplicate wells
of Nunc Maxi-Sorb 96-well plates (Scientific Laboratory
Supplies Ltd, Nottingham, UK) were coated with 100 μl of
diluted antigen preparation, using whole lung homogenate
soluble fractions (10 μg total protein/ml) or the individual
candidate protein antigens shown in Table 2. The plates
were incubated overnight at room temperature. In order to
determine background binding, duplicate wells were
coated overnight with 1% bovine serum albumin (BSA) in
phosphate-buffered saline (PBS) (both from Sigma
Aldrich). The plates were washed three times with wash
buffer containing 0·05% Tween-20 (Sigma Aldrich) in PBS
and then blocked with 300 μl of reagent diluent (1% BSA
in PBS) and incubated for 1 h at room temperature. The
washing step was then repeated. Participants’ serum
samples were diluted to 1 : 40 with reagent diluent. One
hundred μl of diluted serum sample and controls were
added to the wells in duplicate and the plate was incubated
for 2 h at room temperature. The plate was washed three
times as before. One hundred μl of the appropriate
biotinylated secondary antibody : goat anti-human immu-
noglobulin (Ig)A, IgG, IgM or polyclonal Igs (Biosource
International, Nivelles, Belgium) diluted to 1 : 5000 in
reagent diluent was added to each well and incubated for
2 h at room temperature. The plate was washed as before.
One hundred μl of streptavidin–alkaline phosphatase
(Sigma Aldrich) (1 : 500 dilution in reagent diluent)
was added to each well. The plate was incubated for
20 min at room temperature then washed three times.
One hundred μl of the alkaline phosphatase yellow
p-nitrophenyl phosphate (pNPP) liquid substrate (Sigma
Aldrich) was added to each well and the plate was incu-
bated for 20 min at room temperature. The optical density
(OD) was measured after 30 min at 405 nm using a Vmax
Table 2. Candidate antigens – the source, the concentration used and the manufacturing company.
Antigen Source
Concentration
μg/ml Company
Collagen-1 Human lung 10 Sigma, Aldrich, Poole, UK
Collagen-2 Human cartilage 1 Chemicon International, Watford, UK
Collagen-3 Human placenta 10 Sigma, Aldrich, Poole, UK
Collagen-4 Human placenta 10 Sigma, Aldrich, Poole, UK
Collagen-5 Human placenta 10 Sigma, Aldrich, Poole, UK
Fibronectin Human plasma 10 Sigma, Aldrich, Poole, UK
Laminin Human plasma 10 Sigma, Aldrich, Poole, UK
Elastin peptides Human lung elastin peptides 25 Elastin product company, Owensville, MO, USA.
Vitronectin Human plasma 1 Sigma, Aldrich, Poole, UK
Vimentin Human recombinant protein 1 Progen Biotechnik, Heidelberg, Germany
Cytokeratin-8 Human recombinant protein 1 GenWay Biotech, San Diego, CA, USA
Cytokeratin-18 Human recombinant protein 1 GenWay Biotech, San Diego, CA, USA
Thyroglobulin Purified human 10 Sigma, Aldrich, Poole, UK
Bovine serum albumin (BSA) Bovine serum 10 000 Sigma, Aldrich, Poole, UK
Autoantibodies in COPD
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microplate reader (Molecular Devices, Wokingham, UK).
The data are presented as ODs, as it was not possible to
generate a standard curve for specific antibody levels.
Statistics
Differences between groups were assessed by Mann–
Whitney U-test or Student’s t-test using spss version 15·0
and Prism version 3·0 software. P-values ≤0·05 were consid-
ered to be significant.
Results
Serum autoantibodies reactive with human lung
tissue antigens
Human lung samples were homogenized, as described in
Materials and methods, and used in ELISA as the target
antigen preparation for detecting IgG autoantibodies in sera
from COPD patients who smoke (CS), smokers without
airway obstruction (S) and never smokers (NS) (Fig. 1).
The lung samples and the sera were obtained from different
subjects. Six homogenates were used as antigen prepara-
tions: two each from the lung tissues of CS patients
(Fig. 1a,b), S subjects (Fig. 1c,d) and NS subjects (Fig. 1e,f).
The results in Fig. 1 show that, regardless of the source of
the lung antigen preparations, the sera from CS patients
showed significantly and reproducibly lower levels of IgG
antibody binding to lung antigens than the sera from NS
individuals. In all cases, the median levels of IgG anti-lung
antibodies in the sera of S individuals were between the
medians for the NS sera and the CS sera, but were not sig-
nificantly different from either.
The finding that the level of IgG anti-lung antibodies is
highest in the NS sera suggests that these are ‘natural
autoantibodies’ rather than disease-specific autoantibodies,
and that their circulating levels are reduced significantly in
CS patients. An alternative explanation could be that there
is non-specific binding of IgG immunoglobulins to the lung
homogenates, and that the lower levels of IgG binding
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Fig. 1. Detecting serum immunoglobulin (Ig)G
autoantibodies that bind to constituents of
human lung tissue. Sera from smokers with
chronic obstructive pulmonary disease (CS),
smokers (S) and non-smokers (NS) were
analysed by enzyme-linked immunosorbent
assay (ELISA) for IgG antibodies that bind to
human lung tissue homogenates. The sources of
the lung tissue were as follows: (a,b) CS
patients; (c,d) S subjects; (e,f) NS subjects. Each
point represents an individual serum sample,
and the horizontal line is the median optical
density (OD) value of the group; statistical
comparisons between groups were performed
using the Mann–Whitney U-test. The lung
samples and the sera were obtained from
different subjects.
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observed with CS sera are due to a general reduction of cir-
culating levels of IgG in CS patients. The total levels of
serum IgG were therefore determined by nephelometry in
the CS, S and NS sera; the results in Fig. 2 show that there
were no significant differences between the three groups,
indicating that non-specific IgG binding to the lung
homogenates is not the explanation for the differences
observed between groups.
Serum autoantibody reactivity with specific
candidate antigens
Having demonstrated a generalized decrease in IgG
autoantibodies showing reactivity with lung tissue in sera
from CS patients compared to S and NS controls, the reac-
tivity of these sera with a series of potential candidate anti-
gens relevant to lung was investigated. The purified proteins
employed (Table 2) were chosen as candidate antigens on
the basis of previous evidence of their immunogenicity in
various lung diseases and/or their major representation
within lung tissue. BSA was used as the blocking agent in
the ELISA, and the ODs given for binding of serum IgG to
BSA alone were subtracted from the ODs for all candidate
antigens; there was no significant difference in binding to
BSA by IgG in CS, S and NS sera. By contrast, the reactivity
of serum IgG antibodies with collagen-1 (a major
extracellular matrix component of lung tissue) mirrored the
findings for antibody binding to lung homogenates
described above. Thus, the CS sera showed significantly
lower levels of IgG autoantibodies to collagen-1 than the NS
sera, with the S sera showing intermediate levels (Fig. 3a).
None of the other candidate antigens showed this pattern of
reactivity with the sera, with the exception of elastin, to
which overall levels of IgG binding were very low (data not
shown).
Several of the candidate antigens showed high reactivity
with IgG in individual CS and/or S sera; in these cases, posi-
tive binding was defined by sera giving an OD that was at
least 1·5 times the upper limit of the range of ODs given by
the NS sera (indicated by the dotted lines in Fig. 3b,c).
Thus, individual CS and S sera showed strong IgG binding
to cytokeratin-18 and/or collagen-5 (Fig. 3b,c); one S serum
also showed IgG reactivity with collagen-4 (data not
shown).
Autoantibodies sequestered to the lung in COPD
Lung tissue homogenates from CS, S and NS individuals
were treated with glycine-HCl buffer to elute tissue-
associated antibodies, as described in Materials and
methods. These eluates were investigated in ELISA for IgG
autoantibody reactivity with the purified candidate antigens
used previously to detect serum IgG autoantibodies, as
described above. In order to compare the levels of antibod-
ies eluted from different lung specimens, the OD values
generated for IgG binding to candidate lung antigens were
standardized by expressing them as ratios to the OD values
of the same eluates for binding to the negative control
antigen, thyroglobulin. Figure 3d shows that the standard-
ized levels of IgG antibodies specific for collagen-5 were
higher in the eluates from CS lung tissue than from S or NS
lung tissue. No significant differences were found for eluted
antibodies specific for the other candidate antigens tested
(collagen-1, collagen-3, cytokeratin-18, elastin, fibronectin,
vimentin, vitronectin), although this may be at least partly a
consequence of the small number of lung samples available
for elution of antibodies, which is a clear limitation of the
present study. Larger numbers of samples will be required
to determine whether eluted antibodies specific for some of
these other candidate antigens are, in fact, raised in CS
lungs.
Discussion
In this study we show that detectable levels of IgG antibod-
ies that bind to lung tissue components are lower in the cir-
culation of CS patients than in NS subjects. The fact that
such antibodies are detectable (and, indeed, highest) in the
NS group indicates that these are NAAbs that occur natu-
rally in everyone. The same phenomenon was seen for anti-
bodies that bind to collagen-1 specifically; i.e. their
detectable levels were reduced significantly in the sera of CS
patients compared to NS subjects. Collagen-1 is the major
type of collagen in lung tissue [40], and our findings suggest
that collagen-1 is a significant target of the lung-reactive
NAAbs in human sera. Interestingly, a similar observation
was reported by Wood et al. with respect to antibodies to
elastin; i.e. higher levels were detected in NS controls than
in CS patients [28]. Indeed, we also observed significantly
lower levels of IgG antibodies to elastin peptides in CS
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Fig. 2. Total immunoglobulin (Ig)G immunoglobulin levels in sera.
Sera from smokers with chronic obstructive pulmonary disease (CS)
patients, smokers (S) and non-smokers (NS) were assayed for total
IgG levels by nephelometry. Each point represents an individual serum
sample, and the horizontal lines are the median IgG concentrations
(g/l) of the groups; statistical comparisons between groups were
performed using the Mann–Whitney U-test.
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patients’ sera than in NS subjects, but the levels of anti-
elastin detected in our ELISA were generally very low (data
not shown).
A possible explanation of our finding of reduced levels of
lung-reactive NAAbs in CS patients’ sera is that, in COPD,
NAAbs that can bind to a variety of lung constituents
(including collagen-1) are sequestered to the lung from the
circulation. Other explanations for the apparent reduction
of lung-reactive NAAbs in CS patients’ sera are also possi-
ble. For example, binding of circulating antibodies to tissue
constituents released into the bloodstream from inflamed,
damaged lungs in COPD could reduce detection of these
antibodies in ELISA due to their involvement in immune
complex formation. Another possibility is that circulating
NAAbs show higher connectivity in COPD than is normally
the case; i.e. they are more connected into idiotype/anti-
idiotype networks, thereby reducing their availability for
binding to antigens [38,39].
If NAAbs are involved in COPD this leaves open the
question of their role in the disease, which could be either
protective or pathogenic. A physiological anti-inflammatory
function of NAAbs is thought to involve binding to
damaged and senescent cells, thereby promoting their clear-
ance from tissues; an example is the proposed anti-
atherogenic role of NAAbs by binding to oxidized tissue
components [41]. Conversely, NAAbs have been shown to
promote intestinal ischaemia/reperfusion injury through
binding to the damaged tissues and activating complement
[42,43]. Such effects may be tissue-specific [42], and further
studies are required to determine whether NAAbs may
inhibit or promote damage to the lungs in COPD. Thera-
peutic intravenous immunoglobulin (IVIG) preparations
are known to contain NAAbs [44] that may account, at least
in part, for the beneficial effects of treatment with IVIG in
certain autoimmune and inflammatory diseases [45,46].
Thus, if NAAbs are shown to be protective to the lung in
COPD, the possibility of IVIG administration is raised as a
potential therapy for this disease.
It is of note that the results in this study for smokers
without COPD were intermediate between those for
smokers with COPD and never smokers – i.e. serum anti-
bodies of S individuals gave a level of binding to lung tissue
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Fig. 3. Detecting serum and lung-associated immunoglobulin (Ig)G autoantibodies that bind to candidate lung antigens. (a–c) Sera from smokers
with chronic obstructive pulmonary disease (CS), smokers (S) and non-smokers (NS) subjects were analysed by enzyme-linked immunosorbent
assay (ELISA) for IgG antibodies that bind to pure protein antigens [collagen-1, (a); cytokeratin-18, (b); collagen-5 (c)]. Each point represents an
individual serum sample, and the horizontal lines are the median optical density (OD) values of the groups. Statistical comparisons between groups
were performed using the Mann–Whitney U-test. Dashed lines represent 1·5 times the upper limit of the range of ODs given by the NS sera.
(d) Eluates of lung tissue from CS, S and NS subjects were analysed by ELISA for IgG antibodies that bind to pure protein antigens. Each point
represents an individual lung tissue eluate, and the standardized values shown are the ratio of the OD for eluted IgG binding to collagen-5 divided
by the OD for the binding of the same eluted IgG to thyroglobulin (negative control antigen); the horizontal bars are the mean standardized values
of the groups. Significant differences between groups were tested by Student’s t-test.
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intermediate between those of NS subjects and CS patients
(which was not significantly different from either) (Fig. 1).
This suggests that smokers without overt COPD may have
subclinical features of the disease, and our findings are con-
sistent with the increase in bronchus-associated lymphoid
tissue in smokers compared to never smokers [47].
Our results also support the occurrence of DSAAbs in
some CS and S subjects, although the number of subjects
in this study was too low for statistical significance. Even
so, the observation of individual CS and S sera with high
levels of IgG antibodies to cytokeratin-18 and collagen-5
(and also to cytokeratin-8 and collagen-4), compared to
NS sera, is consistent with others’ findings in COPD or
other inflammatory lung diseases [19,29,40,48]. For
example, others have reported the occurrence of antibodies
to cytokeratin-18 in both COPD [29] and in non-allergic
asthma [30]. It is also particularly interesting that we
found antibodies to collagen-5 eluted from lung tissue to
be raised significantly in CS patients compared to S and
NS subjects. Immunity to collagen-5 is also associated with
lung transplant dysfunction and bronchiolitis obliterans
syndrome [40,49–51], lung cancer [52] and experimental
scleroderma [53]. Collagen-5 is a minor collagen in the
lung, where it is sequestered within the major collagen-1
fibrils [40]; thus, it may be its exposure during inflamma-
tion and damage to lung tissues that permits collagen-5 to
be recognized as an autoantigen.
This raises the issue of whether autoimmunity in COPD
is a primary or secondary event in the disease pathogenesis;
it has been argued that autoimmunity in COPD may be sec-
ondary to the release of tissue components from damaged
lung parenchyma rather than autoimmunity initiating this
damage [54]. Even if it were the case that the initial smoke-
induced events involve antigen non-specific inflammation
and tissue damage, this would not necessarily diminish the
potential importance of autoimmunity in the propagation
and transition to a self-perpetuating, smoke-independent
process (which could explain why COPD persists after ces-
sation of smoking). This would be consistent with a mecha-
nism of induction of autoimmunity in COPD that involves
smoke-induced tissue damage and exposure of sequestered
lung autoantigens, as proposed above for collagen-5. This
could be analogous to statin-induced autoimmune myopa-
thy that involves autoimmunity to HMGCoA-reductase that
is up-regulated in muscle tissue as a consequence of the
inhibition of this enzyme by statins; but, once established,
the autoimmune reaction continues, despite statin with-
drawal [55].
A further consideration is whether autoantibodies that
are associated with lung tissue itself (as demonstrated for
anti-collagen-5 in this study) are produced in conventional
lymphoid tissues and sequestered to the lung from the cir-
culation, or whether they are produced by lymphoid struc-
tures that develop within the lung during COPD. This latter
possibility seems highly likely, given the clearly documented
development of lymphoid follicles within the lungs in
COPD [13,14]. These follicles have B cell cores that may be
a source of lung-reactive autoantibodies [56]. It would
therefore be very interesting to investigate the specificity of
antibodies produced by these lung follicular B cells.
A limitation of our study is the relatively small number of
subjects studied, and the results reported here need to be
confirmed in larger cohorts of participants. In addition, the
panel of autoantigens investigated should be expanded in
order to ensure that the profile of autoantibodies detected is
as comprehensive as possible. We are currently aiming to
fulfil these criteria using reverse-phase protein microarray
technology. Direct identification of target antigens within
lung homogenates by Western blotting would also provide
further valuable information.
In summary, this study is consistent with a role for both
NAAbs and DSAAbs (that bind to lung antigens) in the
pathogenesis of COPD. Whether NAAbs ameliorate or exac-
erbate the inflammation and tissue damage remains to be
determined.
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